LVivo Auto EF
AI-powered automatic ejection fraction for point-of-care ultrasound
Software · EmbeddedCompany source
Company profile
About DiA Imaging Analysis Ltd
DiA Imaging Analysis Ltd is a leading global provider of artificial intelligence-powered ultrasound analysis software specializing in cardiac imaging. The company develops advanced AI-based algorithms that automate the evaluation of cardiac ultrasound images, addressing the traditional challenges of manual interpretation and reader variability. Their flagship product, LVivo Seamless, is an FDA-cleared and CE-marked solution that integrates into echocardiography lab workflows to automatically select and analyze optimal cardiac images, generating key clinical indications of both left and right ventricle function. The software is designed to improve efficiency of routine tasks and effectiveness of workflow in echo lab reading environments. DiA's technology has been clinically validated, including a Mount Sinai study that found their cardiac ultrasound AI algorithm comparable to cardiac MRI. The company serves echocardiologists, sonographers, and imaging specialists globally through partnerships with major healthcare technology companies and imaging solution providers. DiA is an IBM Alpha Zone Accelerator Alumni Startup and has established collaborations with industry leaders including IBM Watson Health, Change Healthcare, ScImage, Circle Cardiovascular Imaging, Konica Minolta Healthcare, and Terason. The company's mission is to make AI-based software accessible to clinicians worldwide by integrating it seamlessly into their daily routines and readflow, ultimately improving patient outcomes and care quality.
Company description DiA Imaging Analysis Ltd official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at DiA Imaging Analysis Ltd?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cardiac function assessment
- COVID-19 cardiac complications
- Ejection fraction measurement
- Left ventricle function
- Right ventricle function
Who it serves
- Echo Labs
- Health Systems
- Hospitals
- Imaging Centers
Deployment & integration
Embedded · Hybrid deployment with recorded integration context.
Recorded integration context: Change Healthcare CPACS, Circle Cardiovascular Imaging, IBM Watson Health, Konica Minolta Exa Cardio PACS, ScImage, Terason ultrasound systems.
Geographic context
MarketsEurope · Global · Israel · United States
Company sourceOfficial website
Company milestones
Platform expansion
Partnership with ScImage (June 2022), multi-year agreement with Change Healthcare (March 2022), Mount Sinai clinical validation study (December 2021), partnership with Circle Cardiovascular Imaging (June 2021), integration with Konica Minolta Exa Cardio PACS (November 2020), government grant for COVID-19 ultrasound AI access (May 2020), IBM Watson Health collaboration (December 2019), Terason partnership (August 2019)
Partnerships
Recorded partners
- Change Healthcare
- Circle Cardiovascular Imaging
- IBM Watson Health
- Konica Minolta Healthcare Americas
- ScImage
- Terason
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
LVivo Seamless
AI-based software for automated cardiac ultrasound analysis
Software · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
Evaluation of the LVivo Image Quality Scoring (IQS)NCT05563701 · Sponsor · COMPLETED
Automated Left Ventricular Function Evaluation by LVivoEFNCT01515267 · Sponsor · UNKNOWN
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Workflow efficiency improvement
Automating routine tasks in echo lab reading environment
Reduced reader variability
Providing objective analysis of cardiac scans
Faster analysis
Immediate presentation of clinical indications on PACS viewer
Comparable to cardiac MRI
Mount Sinai validation study
Mount Sinai Health System
Validation of DiA cardiac ultrasound AI algorithm for cardiac function assessment
AI algorithm found comparable to cardiac MRI for cardiac assessment
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Hila Goldman Aslan
CEO and Co-Founder
06 · Company updates
Updates from DiA Imaging Analysis Ltd
Recent articles published on DiA Imaging Analysis Ltd's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.